Cancerforskningsfondet Af 1989

Hannele Tapiovaara

Ettore Appella

Vincent Ellis

Charles Pyke

Michael Ploug

Eeva-Marjatta Salonen

Niels Behrendt

Antti Vaheri

Ann Louring Roldan

Francesco Blasi

Maria Vittoria Cubellis

Peter Kristensen

Maria Teresa Masucci

Ross W Stephens

Wolf-Dieter Schleuning

Keld Dano Slashed

Ebbe Ro Slashednne

Keld Dan&oslash;

Lisbeth Birk M&oslash;ller

Leif R&oslash;ge Lund

Ebbe R&oslash;nne

L&aacute;szlo Patthy

Wd Schleuning

Laszlo Patthy

Leif Ro Lund

Lisbeth Birk Mo Slashedller

Jari Pollanen

Jari P&ouml;ll&auml;nen

Activation of plasminogen to plasmin is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator receptor are provided.

Urokinase-type plasminogen activator receptor

Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.

Vectors and methods for recombinant production of uPA-binding fragments

Growing community of inventors

Helsinki, Finland

Hannele Tapiovaara